Elecsys® Troponin T hs Gen 6

IVD For in vitro diagnostic use.
Elecsys<sup>®</sup> Troponin T hs Gen 6
Contact us
A woman experiencing chest pain after exercise indicates a potential for Elecsys Trop T version 6 testing

Elecsys® Troponin T hs Gen 6: ACS care with unprecedented diagnostic confidence

As one of the top three reasons for emergency care visits chest pain represents a significant burden on healthcare services.1 Yet only one in every ten patients will actually be diagnosed with myocardial infarction (MI).2 The ability to quickly and reliably identify those patients who are suffering from acute myocardial infarction (AMI) is crucial in ensuring the best possible outcomes and protecting overstretched healthcare services.

High-sensitive Troponin T is a well-established and guideline-recommended biomarker for diagnosing acute coronary syndrome (ACS).3 With a 30-year legacy in troponin innovation, Roche was the first company in the world to introduce high-sensitivity troponin tests, and the first to receive FDA approval.4-13 Building on this legacy, the Elecsys® Troponin T hs Gen 6 (TnT hs Gen 6) assay sets a new benchmark in terms of precision, robustness, and global validation.14

Elecsys® Troponin T hs Gen 6 enables clinicians to detect even the smallest elevations in troponin levels—a critical biomarker for the diagnosis of myocardial injury—with high confidence.15 The assay’s scientific robustness and clinical validation support its safe and effective use across different triage pathways.16-18 This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity.

Benefits at a glance

Benefits at a glance

An icon of a test tube with a checkmark, representing the precision of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)

High sensitivity at very low troponin levels for accurate, timely results, helping to boost confidence in decision-making and enhance triage efficiency.14,15

heart pain

Improved patient classification compared to the previous assay generation resulting in fewer patients identified with myocardial injury, reducing the potential of over-classification and unnecessary diagnostic procedures by approximately 8%.17

icon for testing efficiency

Efficient patient triage: By supporting the ESC 0/1-hour and 0/2-hour algorithms, Elecsys® Troponin T hs Gen 6 provides a validated framework that aligns assay performance with international standards.16-20

  • 76% of suspected ACS patients can be triaged (rule-in or rule-out) with the ESC 0/1h algorithm using assay-specific cutoffs, potentially accelerating the AMI diagnosis process and reducing Emergency Department (ED) workload.17,18

Rule-out Observe Rule-in
56% of suspected NSTEMI patients with high negative predictive value of 99.9% 24% of patients requiring further assessment 20% of patients with a high positive predictive value of 73%


  • Strong prognostic performance, improving triage efficiency and safety on short- and long-term follow-up. It supports clear risk stratification to allow for safe discharge of the rule-out group and to prioritize care for rule-in/observe groups. 17,18, 21

  • 41% of patients could be ruled out with a single blood sample using a cutoff of 13ng/L. In conjunction with clinical assessment, the single sample rule-out pathway has the potential to support the safe and early discharge from the emergency department.16
An icon of multiple test tubes, representing the robustness of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)

  • Market-leading resistance to interferences from hemoglobin, for less resampling15,22

  • 3-level quality control14,15

  • Low lot-to-lot and platform variability, demonstrating robustness and reproducibility, regardless of the analyzer or setting14,15

  • Long-term compliance with current regulatory standards (National Institute of Standards and Technology reference materials), enhancing traceability and confidence in results15
An icon of a clipboard with a checkmark, representing the validation of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)

Our 30-year legacy in troponin research is the backbone of Elecsys® Troponin T hs Gen 6, validated in the comprehensive TSIX-study program. 

TSIX is the first global study program to establish and validate diagnostic cutoffs that work across diverse populations, settings, genders, and sample types.19 The cutoffs derived from REF-TSIX enable standardized interpretation of troponin results worldwide and helps to simplify use compared to assays with varying sample type cutoffs.19

A globe icon, illustrating the global study to validate one diagnostic cutoff of Elecsys cardiac Troponin T hs Gen 6

4147 study subjects

An icon of a couple illustrating the one overall diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Overall

27 ng/L

An icon of a woman’s head illustrating the female diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Female

18 ng/L

An icon of a man’s head illustrating the male diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Male

32 ng/L

Validated in more than 11,000 patients across > 10 countries

Elecsys® Troponin T hs Gen 6 has shown consistent performance across different triage pathways and provides clinicians stronger confidence in every ACS decision.16,17,20,21

Expanding the evidence base for hs-Troponin T

Through a series of completed and ongoing studies, we are exploring the role of hs-Troponin T in evolving clinical contexts:

  • Peri-operative myocardial injury23,24

  • Patients with renal dysfunction20,25

  • Asymptomatic or chronic populations26

  • Long-term cardiovascular risk prediction17,20,21

Related categories

Downloads

Use left and right arrow keys to scroll between the tabs

Overview

Ordering information

Technical documents

Access important product documentation including relevant certificates and other resources.

After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Document repository artboard
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Compatible products

No products found for this filter.
No products found for this filter.

Related Products

...
    ...

    Rapid algorithms and early rule-out with novel Gen 6 high-sensitivity troponin assay

    headshot of Lori Daniels

    Insights into the global TSIX study program: An interview with Prof. Lori Daniels

    How high-sensitivity Troponin T is reshaping ACS diagnosis and ED efficiency, a roundtable discussion with Pierre Sabouret (FR), Giuseppe Galati (IT), Diego Segura Rodriguez (ES)

    Elevating AMI diagnosis: A deep dive into the global TSIX study: Interviews with Christian Müller, Frank Peacock, Evangelos Giannitsis, and Mamas Mamas

    You might be interested in

    ...
      ...

      Contact us

      Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

      Contact us

      References

      1. Weiss AJ, Jiang J. Agency for Healthcare Research and Quality, Most Frequent Reasons for Emergency Department Visits. 2018. Available from: https://hcup-us.ahrq.gov/reports/statbriefs/sb286-ED-Frequent-Conditions-2018.pdf
      2. Fanaroff AC, et al. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. 2015 Nov 10;314(18):1955-65. 
      3. European Society of Cardiology. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023 Aug 25;44:3720–3826.
      4. 4. Collinson P. Update on global conversion to high sensitivity cardiac troponin assays. J Lab Precis Med. 2023 Apr 30;8:15.
      5. F. Hoffmann-La Roche Ltd. Elecsys Troponin T Gen 5 Method Sheet. (v4.0). 2024.
      6. F. Hoffmann-La Roche Ltd. Elecsys Troponin T Gen 5 STAT Method Sheet. (v3.0). 2018. 
      7. Chew D, et al. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes. Circulation. 2019 Nov 5;140(19):1543–56. 
      8. Stoyanov K, et al. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardio Care. 2020 Feb;9(1):39–51. 
      9. Twerenbold R, et al. Outcome of Applying the ESC 0 /1-hour Algorithm in Patients With Suspected Myocardial Infarction. JACC. 2019 Jul 30;74:483–94. 
      10. Danese E, et al. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016 May;4(10):194. 
      11. Reichlin T, et al. One-Hour Rule-out and Rule-in of Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin T. Arch Intern Med. 2012 Sep 10;172(16):1211–1218. 
      12. Reichlin T, et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. CMAJ. 2015 May 19;187(8):E243–52.
      13. Mueller C, et al. Multicenter Evaluation of a 0-Hour /1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016Jul;68(1):76–87. 
      14. Knoll M, et al. Analytical Performance Evaluation of the Cardiac Troponin T High Sensitivity Gen 6 Assay, The Journal of Applied Laboratory Medicine, 2026; jfag031, https://doi.org/10.1093/jalm/jfag031
      15. F. Hoffmann-La Roche Ltd. Elecsys Troponin T hs Gen 6 Method Sheet. (v3.0). 2026.
      16. Thurston F. Early rule-out of myocardial infarction with the novel Troponin T hs Gen 6 assay. Presented at EUSEM Congress 2025, 28 September – 1 October; Vienna, Austria.
      17. Koechlin L et al. High-Sensitivity Cardiac Troponin T -gen6 Assay in Suspected Myocardial Infarction Diagnostic Accuracy, Cutoffs, and Clinical Implications. doi: 10.1016/j.jacc.2025.12.052.
      18. Peacock WF, et al. Primary results of PERFORM-TSIX, a prospective, international, observational, longitudinal cohort study evaluating clinical performance of the next generation cardiac troponin T high-sensitivity Gen 6 assay in acute myocardial infarction. Presented at EUSEM Congress 2025, 28 September – 1 October; Vienna, Austria.
      19. Daniels LB, et al. "Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study." Clinical Chemistry.(2026):hvag011.
      20. Daniels LB et al. "Clinical performance of the next generation Elecsys Troponin T high-sensitivity Gen 6 assay in acute coronary syndrome (PERFORM-TSIX): study design." Clinical Research in Cardiology. 2026:1-12.
      21. Völschow B, et al. Diagnostic Validation of a novel High-Sensitivity Cardiac Troponin T Assay. NCT02355457 [Manuscript in preparation] Accepted in EHJ Acute Cardiovascular Care 2026.
      22. F. Hoffmann-La Roche Ltd. Hemoglobin interference comparison. Data on file.
      23. ClinicalTrials.gov. Monitoring of Vital Signs for Phenotyping of Perioperative Myocardial Infarction/Injury After Noncardiac Surgery (PMI-VITAL) [Internet; cited 2026 Jan 15]. Available from: https://clinicaltrials.gov/study/NCT05866874
      24. ClinicalTrials.gov. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study 2 (VISION-2) [Internet; cited 2026 Jan 15]. Available from: https://clinicaltrials.gov/study/NCT07300579
      25. ClinicalTrials.gov. A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome (PERFORM-TSIX) [Internet; cited 2026 Feb 15]. Available from: https://clinicaltrials.gov/study/NCT06734117
      26. ClinicalTrials.gov. Hamburg City Health Study - a German Cohort Study (HCHS) [Internet; cited 2026 Jan 15]. Available from: https://clinicaltrials.gov/study/NCT03934957